| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 [J. G., R. M.]; Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, 4032 Australia [K. M. F., P. V. Z.]; and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75235 [J. D. M.]
This study was performed to determine the frequency of inactivation and clinical correlates in non-small cell lung cancer (NSCLC) of three known tumor suppressor genes [TSGs; RB, MTS1/CDKN2 (p16), and p53] and various regions of 3p loss of heterozygosity (LOH) as other major potential TSG sites. Paraffin sections from 103 resected NSCLCs were analyzed for expression of pRB, p16, and p53 by immunohistochemistry, whereas DNA from tumor and normal tissue were tested for LOH at 3p25–26, 3p21, and 3p14. Previously published LOH data for 5q, 11p, 17q, and 18q were also available. Loss of pRB or p16 expression and overexpression of p53 were considered abnormal. The immunohistochemical and LOH data were correlated with a variety of clinical parameters including stage, age, sex, smoking history, and survival. With respect to pRB, p16, and p53, the tumors could be grouped into four categories: normal for all three proteins (21%); abnormal for pRB or p16 and normal for p53 (30%); normal for pRB and p16 and abnormal for p53 (20%); and abnormal in both pathways (28%). Aberrant expression of pRB, p16, p53, and 3p LOH, either individually or in combination, was not associated with survival differences or any other clinical parameters, with the exception that pRB/p16 abnormalities were more common in older patients (P = 0.0005). pRB and p16 expression showed a strong inverse correlation (P = 0.002), whereas there was no correlation between expression of pRB, p16, and p53. Abnormal expression of any of the three genes inversely correlated with K-ras codon 12 mutations (P = 0.004), but not with 3p LOH or LOH at other TSG loci. We conclude that resectable NSCLCs show distinct patterns of TSG inactivation, but that no clear clinical correlates exist either alone or in combination for pRB, p16, p53, and 3p abnormalities.
This article has been cited by other articles:
|
|
 |
|
  S Mohamed, K Yasufuku, T Nakajima, K Hiroshima, R Kubo, A Iyoda, S Yoshida, M Suzuki, Y Sekine, K Shibuya, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response Thorax, July 1, 2008; 63(7): 642 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, V. Pishchik, et al. Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. Clin. Cancer Res., October 1, 2006; 12(19): 5777 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Esposito, A Baldi, A De Luca, G Tonini, B Vincenzi, D Santini, P Persichetti, A Mancini, G Citro, F Baldi, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer J. Clin. Pathol., July 1, 2005; 58(7): 734 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Burke, D. B. Flieder, D. G. Guinee, E. Brambilla, A. N. Freedman, W. P. Bennett, R. T. Jones, A. Borkowski, N. A. Caporaso, M. Fleming, et al. Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-Small Cell Lung Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 232 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Marsit, M. Hasegawa, T. Hirao, D.-H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson, and K. T. Kelsey Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non-Small-Cell Lung Cancer Cancer Res., December 1, 2004; 64(23): 8702 - 8707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kim, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung Carcinogenesis, November 1, 2004; 25(11): 2165 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Esposito, A Baldi, G Tonini, B Vincenzi, M Santini, V Ambrogi, T C Mineo, P Persichetti, G Liuzzi, V Montesarchio, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer J. Clin. Pathol., January 1, 2004; 57(1): 58 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Cheng, S.-C. Lee, H.-J. Harn, C.-J. Chen, Y.-C. Chang, J.-C. Chen, and C.-P. Yu Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer Eur. J. Cardiothorac. Surg., February 1, 2003; 23(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bepler, A. Gautam, L. M. McIntyre, A. F. Beck, D. S. Chervinsky, Y.-C. Kim, D. M. Pitterle, and A. Hyland Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikezoe, C. W. Miller, S. Kawano, A. Heaney, E. A. Williamson, J. Hisatake, E. Green, W. Hofmann, H. Taguchi, and H. P. Koeffle Mutational Analysis of the Peroxisome Proliferator-activated Receptor {{gamma}} Gene in Human Malignancies Cancer Res., July 1, 2001; 61(13): 5307 - 5310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B. Gao, D. Randle, M. Kondo, A. Virmani, S. Bader, et al. Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression J Natl Cancer Inst, May 2, 2001; 93(9): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zöchbauer-Müller, K. M. Fong, A. Maitra, S. Lam, J. Geradts, R. Ashfaq, A. K. Virmani, S. Milchgrub, A. F. Gazdar, and J. D. Minna 5' CpG Island Methylation of the FHIT Gene Is Correlated with Loss of Gene Expression in Lung and Breast Cancer Cancer Res., May 1, 2001; 61(9): 3581 - 3585. [Abstract] [Full Text]
|
|
|
|
|
|
D.-H. Kim, H. H. Nelson, J. K. Wiencke, S. Zheng, D. C. Christiani, J. C. Wain, E. J. Mark, and K. T. Kelsey p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer Cancer Res., April 1, 2001; 61(8): 3419 - 3424. [Abstract] [Full Text]
|
|
|
|
|
|
S. Zöchbauer-Müller, K. M. Fong, A. K. Virmani, J. Geradts, A. F. Gazdar, and J. D. Minna Aberrant Promoter Methylation of Multiple Genes in Non-Small Cell Lung Cancers Cancer Res., January 1, 2001; 61(1): 249 - 255. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hirao, H. H. Nelson, T. D. S. Ashok, J. C. Wain, E. J. Mark, D. C. Christiani, J. K. Wiencke, and K. T. Kelsey Tobacco Smoke-induced DNA Damage and an Early Age of Smoking Initiation Induce Chromosome Loss at 3p21 in Lung Cancer Cancer Res., January 1, 2001; 61(2): 612 - 615. [Abstract] [Full Text]
|
|
|
|
|
|
M. Seike, A. Gemma, Y. Hosoya, S. Hemmi, Y. Taniguchi, Y. Fukuda, N. Yamanaka, and S. Kudoh Increase in the Frequency of p16INK4 Gene Inactivation by Hypermethylation in Lung Cancer during the Process of Metastasis and Its Relation to the Status of p53 Clin. Cancer Res., November 1, 2000; 6(11): 4307 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text]
|
|
|
|
|
|
H. B. Salvesen, S. Das, and L. A. Akslen Loss of Nuclear p16 Protein Expression Is Not Associated with Promoter Methylation but Defines a Subgroup of Aggressive Endometrial Carcinomas with Poor Prognosis Clin. Cancer Res., January 1, 2000; 6(1): 153 - 159. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geradts, R. Maynard, M. J. Birrer, D. Hendricks, S. L. Abbondanzo, K. M. Fong, J. C. Barrett, and D. P. Lombardi Frequent Loss of KAI1 Expression in Squamous and Lymphoid Neoplasms : An Immunohistochemical Study of Archival Tissues Am. J. Pathol., June 1, 1999; 154(6): 1665 - 1671. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
